Welcome to the Frontpage

Cellmid Limited (ASX:CDY) is a biotechnology company listed on the Australian Stock Exchange. The company is committed to the commercialization of its technology portfolio around midkine, a heparin-binding growth factor, and its inhibitors for both therapeutic and diagnostic applications.

CDY holds the largest and most comprehensive intellectual property portfolio globally in relation to midkine, a validated therapeutic and diagnostic target in inflammation and cancer.

CDY is actively looking for partners to commercialise the Company’s significant midkine intellectual property assets in ischemia, cancer and autoimmune diseases. In addition CDY’s broad cancer marker patents are also available for licensing.

2009 Annual Report

Interactive Investor Roadshow eKit

SHARE PRICE

Cellmid Ltd (CDY):

more...

NEWS

Appendix 4C Quarterly Report

more...

Appendix 3B

New issue announcement

more...

Cellmid and Pacific Edge Sign Cancer Diagnostic License

Sydney, 19 May 2010 - Cellmid Limited (ASX:CDY) and Pacific Edge Biotechnology Limited (PEB), have entered into a non-exclusive license agreement for the use of CDY’s midkine technology in PEB’s bladder cancer test. Cellmid will receive upfront and milestone payments in addition to royalties on product sales.

more...

Joint Research Agreement Signed with Kumamoto University

Sydney, 21 April 2010: CDY and Kumamoto University signed a Joint Research Agreement for the testing of midkine levels in 3,000 sera samples.

more...

Study Results Support AMI Trials

Download the latest Cellmid ASX Announcement

more...

Validated Cancer Marker Presentation

Sydney March 19, 2010: Darren Jones head of product development of Cellmid Limited presented at the Pharma R&D Partnering World Asia conference.

more...

CDY Signs Collaboration for Heart Attack Treatment

Sydney March 4, 2010: Cellmid (ASX:CDY) today signed research, development and collaboration agreements with Pharmahungary for the pre-clinical and early clinical validation programs for midkine to treat heart attack (acute myocardial infarction or AMI).

more...

Cellmid News

Sydney February 24, 2010: Update on Cellmid's recent progress...

more...